#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cutaneous T-cell lymphoma stage II Bronchopulmonary dysplasia Peripheral T-cell lymphoma unspecified Gastric cancer Mixed-type liposarcoma Hepatic angiosarcoma Spinal cord injury cervical Autoimmune disorder Neuronal ceroid lipofuscinosis Nephropathy Burkitt's lymphoma Desmoid tumour Thrombocytopenia Familial dilated cardiomyopathy Nodal marginal zone B-cell lymphoma More trials…

    Learn about Rare Diseases

    Urea cycle disorder Gastrointestinal stromal tumour – Basic Information Hairy cell leukaemia recurrent Krabbe’s disease – Trials in Disease Congenital nephrogenic diabetes insipidus – Trials in Disease Wiskott-Aldrich syndrome – Trials in Disease Mantle cell lymphoma stage II Skin angiosarcoma Lymphangiosarcoma Choroid melanoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    TUB-030 Gtaexs617 Bnt314 Methotrexate Sodium Lasofoxifene Mbf-118 Pemetrexed Disodium OMECAMTIV MECARBIL Pembrolizumab AMODIAQUINE Dexchlorpheniramine Maleate Setmelanotide 99MTC-EUK-(SO3)CY5-MAS3 L-PROLINE Ixekizumab Immunostimulants Lerodalcibep Timrepigene Emparvovec Triptorelin Tapderimotide More therapies…

    Learn about Your Condition

    Petit mal epilepsy Malignant mast cell neoplasm Metastases to peritoneum Ovarian cancer stage III Mucopolysaccharidosis I Schizophrenia Metastatic malignant melanoma Non-Hodgkin's lymphoma Mantle cell lymphoma stage III Small fibre neuropathy Neurodevelopmental disorder Organ donor Bone sarcoma Irritable bowel syndrome Triple negative breast cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Asklepios Kliniken Hamburg GmbH

Asklepios Kliniken Hamburg GmbH

Eissendorfer Pferdeweg 52, Heimfeld, Hamburg, 21075, Germany

Want to learn more about this study or check if you can participate? Contact us.

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer metastatic
    • Endometrial cancer
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    • Paclitaxel
    Belgium Denmark Finland France Germany Greece +5

  • A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Fluorouracil
    Belgium Denmark France Germany Italy The Netherlands +2

  • A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bile duct cancer
    Investigated Drugs:
    • Cisplatin
    • Durvalumab
    • Gemcitabine
    Belgium France Germany Italy The Netherlands Poland +1

  • A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Pembrolizumab
    Germany

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Bevacizumab
    • Fluorouracil
    Belgium Czechia France Germany Hungary Italy +2

  • Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Folic Acid
    • Zanidatamab
    • Fluorouracil
    Germany

  • A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • FRUQUINTINIB
    • Tipiracil Hydrochloride
    • Trifluridine
    France Germany Spain

  • A Study of TGD001 in Patients with Acute Ischemic Stroke to Test Safety and Effectiveness

    Recruiting

    1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • UROKINASE, CATALYTIC DOMAIN, FUSED WITH A SINGLE-CHAIN ANTIBODY AGAINST VON WILLEBRAND FACTOR
    • Sodium Chloride Solution 0.9%
    Germany Poland Spain

  • Study of alteplase and tenecteplase for intravenous thrombolysis in patients with ischemic stroke who are taking direct oral anticoagulants

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Alteplase
    • Tenecteplase
    Austria Belgium Finland France Germany The Netherlands +3
Previous Page
1 2 3 4 … 13
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!